Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with locally advanced or metastatic ROS1-positive NSCLC after at least one prior ROS1 tyrosine kinase inhibitor.
LAMPGEN ANALYSIS
Why it matters
The indication adds a ROS1-directed option after prior targeted therapy. ARROS-1 included cohorts with different numbers of prior ROS1 inhibitors, a key distinction when discussing sequencing.
What research teams should watch
Verify ROS1 status and capture each prior inhibitor, progression location and CNS imaging. Avoid drawing comparative rankings from separate single-arm studies.
PRIMARY RECORDS